Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Clinical stage drug development company Pharmaxis (PXS) has opened a $2 million share purchase plan (SPP) today after raising $7.2 million through a placement
  • The money will fund phase two trials using PXS-5505 to treat bone marrow and liver cancer
  • Pharmaxis is also progressing the PXS-6302 topical drug to phase 1C trial, which may improve the function and appearance of scarring
  • Shares in Pharmaxis closed at 10.5 cents today, the same price as the placement and SPP

Clinical stage drug development company Pharmaxis (PXS) has opened a $2 million share purchase plan (SPP) in the wake of raising $7.2 million through a placement.

The money will fund phase two trials: One using PXS-5505 to treat bone marrow cancer, the other using the same drug to treat liver cancer as a first-line treatment used in tandom with chemotherapy.

Pharmaxis CEO Gary Phillips said the placement was well supported and the SPP opens today.

“We hope there’ll be demand there to fill up the target of $2 million and that, together with the Placement, gives us the cash balance to make sure we can deliver both clinical trial results by the end of next year,” Mr Phillips said.

Pharmaxis is also progressing the PXS-6302 topical drug through to phase 1C trial.

It has the potential to improve the function and appearance of scarring.

Shares in the SPP will be issued at 10.5 cents each, in line with the placement, which represents a 12.4 per cent discount to the volume weighted average price of 11.98 cents on Friday, November 12.

Shares were trading on market at the same 10.5 cents at the close of today’s session.

PXS by the numbers
More From The Market Herald

" Leigh Creek Energy (ASX:LCK) signs offtake HoA with Daelim, shares spike

Leigh Creek Energy (LCK) stock has risen after the company signed a heads of agreement (HoA) with Daelim, a South Korean contractor, for
PolarX (ASX:PXX) - Managing Director, Frazer Tabeart

" Polar X (ASX:PXX) completed four exploration programs in Nevada and Alaska

PolarX (PXX) has successfully completed exploration programs at its Caribou Dome copper project in Alaska and its Humboldt-Range gold-silver project in Nevada.
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert

" Rhythm Biosciences (ASX:RHY) achieves CE Mark for ColoSTAT

Cancer diagnostic technology company Rhythm Biosciences (RHY) has achieved CE Mark certification for ColoSTAT.

" GTI Resources (ASX:GTR) begins drilling at Thor

GTI Resources (GTR) has begun drilling at the Thor ISR uranium project in Wyoming’s Great Divide Basin.